AIER EYE HOSPITAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.98 CNY | +0.54% |
|
+0.62% | -17.95% |
| Apr. 26 | Aier Eye Hospital Group Co., Ltd. Announces Profit Distribution Proposal for 2023 | CI |
| Apr. 26 | Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.33 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.86 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -17.95% | 16.61B | B+ | ||
| +5.41% | 12.48B | B | ||
| +4.48% | 11.7B | B+ | ||
| +1.79% | 10.07B | B+ | ||
| +28.70% | 8.59B | B | ||
| -4.37% | 7.7B | A- | ||
| +21.11% | 7.3B | D | ||
| +4.01% | 6.56B | B- | ||
| +45.72% | 4.55B | - | ||
| -3.49% | 4.38B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300015 Stock
- Ratings Aier Eye Hospital Group Co., Ltd.